Tag : EVOLOCUMAB

CONFERENCE UPDATE

Evolocumab reduces first MACE in high-risk patients without established atherosclerosis: Subgroup analysis from the VESALIUS-CV trial
A prespecified subgroup analysis from the VESALIUS-CV trial showed that evolocumab significantly reduced first major adverse cardiovascular events (MACE) in high-risk patients with diabetes without established atherosclerosis. Over 5 years, evolocumab lowered median low-density lipoprotein cholesterol (LDL-C) to 44mg/dL and reduced 3-point MACE, cardiovascular death, and all-cause mortality, supporting earlier lipid-lowering intensification.